Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
AbstractThe use of pharmacogenomics to personalize drug therapy has been a long-sought goal for warfarin and tamoxifen. However, conflicting evidence has created reason for hesitation in recommending pharmacogenomics-guided care for both drugs. This review will provide a summary of the evidence to date on the association between cytochrome P450 enzymes and the clinical end points of warfarin and tamoxifen therapy. Further, highlighting the clinical experiences that we have gained over the past ten years of running a personalized medicine program, we will offer our perspectives on the utility and the limitations of pharmacogenomics-guided care for warfarin and tamoxifen therapy. View Full-Text
Share & Cite This Article
Wigle, T.J.; Jansen, L.E.; Teft, W.A.; Kim, R.B. Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. J. Pers. Med. 2017, 7, 20.
Wigle TJ, Jansen LE, Teft WA, Kim RB. Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. Journal of Personalized Medicine. 2017; 7(4):20.Chicago/Turabian Style
Wigle, Theodore J.; Jansen, Laura E.; Teft, Wendy A.; Kim, Richard B. 2017. "Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen." J. Pers. Med. 7, no. 4: 20.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.